[go: up one dir, main page]

WO2013171729A3 - Aryl and heteroaryl amide compounds as ror gamma t modulator - Google Patents

Aryl and heteroaryl amide compounds as ror gamma t modulator Download PDF

Info

Publication number
WO2013171729A3
WO2013171729A3 PCT/IB2013/058108 IB2013058108W WO2013171729A3 WO 2013171729 A3 WO2013171729 A3 WO 2013171729A3 IB 2013058108 W IB2013058108 W IB 2013058108W WO 2013171729 A3 WO2013171729 A3 WO 2013171729A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulator
ror
aryl
amide compounds
ror gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/058108
Other languages
French (fr)
Other versions
WO2013171729A2 (en
Inventor
Sachin Sundarlal Chaudhari
Abraham Thomas
Neelima Khairatkar-Joshi
Malini Bajpai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Glenmark Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals SA filed Critical Glenmark Pharmaceuticals SA
Publication of WO2013171729A2 publication Critical patent/WO2013171729A2/en
Publication of WO2013171729A3 publication Critical patent/WO2013171729A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present disclosure is directed to compounds of Formula (I), and pharmaceutically acceptable salts thereof, as modulator of retinoid-related orphan receptor gamma t (RORϒt). These compounds prevent, inhibit, or suppress the action of RORϒt and are therefore useful in the treatment of RORϒt mediated disease, disorder, syndrome or condition such as pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases or cancer.
PCT/IB2013/058108 2013-01-08 2013-08-29 Aryl and heteroaryl amide compounds as rorgamat modulator Ceased WO2013171729A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN55/MUM/2013 2013-01-08
IN55MU2013 2013-01-08
US201361760301P 2013-02-04 2013-02-04
US61/760,301 2013-02-04
IN811MU2013 2013-03-19
IN811/MUM/2013 2013-03-19

Publications (2)

Publication Number Publication Date
WO2013171729A2 WO2013171729A2 (en) 2013-11-21
WO2013171729A3 true WO2013171729A3 (en) 2014-02-06

Family

ID=49584403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/058108 Ceased WO2013171729A2 (en) 2013-01-08 2013-08-29 Aryl and heteroaryl amide compounds as rorgamat modulator

Country Status (1)

Country Link
WO (1) WO2013171729A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2727191C2 (en) * 2015-06-05 2020-07-21 Лид Фарма Холдинг Б.В. ROR GAMMA (RORγ) MODULATORS
RU2727698C2 (en) * 2015-06-05 2020-07-23 Лид Фарма Холдинг Б.В. ROR GAMMA (RORγ) MODULATORS
US11299456B2 (en) * 2016-12-05 2022-04-12 Lead Pharma Holding B.V. ROR gamma (RORγ) modulators

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150092244A (en) 2012-12-06 2015-08-12 글락소 그룹 리미티드 Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
HRP20181291T1 (en) * 2013-08-02 2018-10-19 Pfizer Inc. HETEROBICYCLOARYL INHIBITORS RORC2 AND THEIR USE
WO2015052675A1 (en) * 2013-10-10 2015-04-16 Glenmark Pharmaceuticals S.A. Substituted dihydro-benzimidazole compounds as ror gamma modulators
EA030393B1 (en) 2013-12-05 2018-07-31 ЛИД ФАРМА СЕЛ МОДЕЛЗ АйПи Б.В. ROR GAMMA (RORγ) MODULATORS
TW201605797A (en) 2013-12-10 2016-02-16 葛蘭馬克製藥公司 Bicyclic heteroarylcompounds as ROR gamma modulators
LT3102576T (en) 2014-02-03 2019-08-12 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ror-gamma
CN104926733B (en) * 2014-03-18 2019-05-10 北京韩美药品有限公司 Compound as ROR gamma modulators
NZ724602A (en) * 2014-03-27 2022-12-23 Piramal Entpr Ltd Ror-gamma modulators and uses thereof
AP2016009542A0 (en) 2014-04-16 2016-11-30 Glenmark Pharmaceuticals Sa Aryl and heteroaryl ether compounds as ror gamma modulators
KR20170012388A (en) 2014-05-28 2017-02-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Novel compounds
CR20160549A (en) 2014-05-28 2017-04-28 Glaxosmithkline Ip Dev Ltd COMPOUNDS DERIVED FROM N- (3 - ((4- (TETRAHYDROFURANE / TETRAHYDROPIRANE-3-CARBONYL) PIPERAZIN-1-IL) METHYL) PHENYL) ACTIVE FORMAMENTS AS MODULATORS OF THE GAMMA ORPHANEO RECEPTOR (RORY) RELATED.
ES2710487T3 (en) 2014-05-28 2019-04-25 Glaxosmithkline Ip Dev Ltd Piperazine derivatives as ror-gamma modulators
MA40759A (en) 2014-09-26 2017-08-01 Pfizer PYRROLOPYRIDINE-SUBSTITUTED BY METHYL AND TRIFLUOROMETHYL RORC2 MODULATORS AND THEIR METHODS OF USE
EA031967B1 (en) 2014-10-14 2019-03-29 Вайтаи Фармасьютиклз, Инк. Dihydropyrrolopyridine inhibitors of ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TW201625588A (en) * 2014-11-05 2016-07-16 第一三共股份有限公司 Cyclic amine derivative
EP3268087A4 (en) 2015-03-12 2018-08-29 The Regents of the University of California METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
SMT202100286T1 (en) 2015-05-15 2021-07-12 Aurigene Discovery Tech Ltd Substituted tetrahydroquinolinone compounds as ror gamma modulators
WO2016193894A1 (en) 2015-05-29 2016-12-08 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using ror- gamma inhibitors
EP3101007A1 (en) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101009A1 (en) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
WO2017021879A1 (en) * 2015-08-03 2017-02-09 Glenmark Pharmaceuticals S.A. Novel compounds as ror gamma modulators
DK3331876T3 (en) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc MODULATORS OF ROR-GAMMA
JP2018526372A (en) * 2015-08-28 2018-09-13 グレンマーク・ファーマシューティカルズ・エスエー Novel carbocyclic compounds as ROR gamma modulators
RU2760373C2 (en) 2015-09-18 2021-11-24 Какен Фармасьютикал Ко., Лтд. Biaryl derivative and drug containing it
WO2017051319A1 (en) * 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
MX385332B (en) 2015-11-20 2025-03-18 Vitae Pharmaceuticals Llc ROR-GAMMA MODULATORS.
JP6448867B2 (en) 2015-12-15 2019-01-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Isoindole compounds
TW202220968A (en) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 Modulators of ror-gamma
TW201803869A (en) 2016-04-27 2018-02-01 健生藥品公司 6-aminopyridin-3-yl thiazoles as modulators of ROR[gamma]t
WO2017199103A1 (en) * 2016-05-18 2017-11-23 Glenmark Pharmaceuticals S.A. Benzamide compounds as ror gamma modulators
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
AR109042A1 (en) 2016-07-14 2018-10-24 Cadila Healthcare Ltd RORg MODULAR COMPOUNDS
TW201811760A (en) 2016-07-14 2018-04-01 印度商卡迪拉保健有限公司 Novel cyclopropyl derivatives
US10954215B2 (en) 2016-12-13 2021-03-23 Boehringer Ingelheim International Gmbh Compounds as modulators of ROR gamma
WO2018116285A1 (en) 2016-12-23 2018-06-28 Glenmark Pharmaceuticals S.A. Substituted morpholine derivatives as ror gamma modulators
WO2018145653A1 (en) * 2017-02-09 2018-08-16 复旦大学 Biaryl compound, preparation method and use therefor
CN108863850B (en) * 2017-02-09 2021-05-18 复旦大学 Biaryl compound and its preparation method and use
WO2018185675A1 (en) 2017-04-04 2018-10-11 Glenmark Pharmaceuticals S.A. Substituted oxoazetidine analogues as ror gamma modulators
US11034654B2 (en) 2017-06-14 2021-06-15 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of ror gamma
UA126583C2 (en) 2017-07-24 2022-11-02 Вітае Фармасьютікалс, Ллс INHIBITORS OF ROR<font face="Symbol">g</font>
SMT202200134T1 (en) 2018-03-08 2022-05-12 Incyte Corp Aminopyrazine diol compounds as pi3k-y inhibitors
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
JP2021527660A (en) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ．ベー． Phenyl and pyridinyl substituted imidazoles as modulators of RORγt
EP3790865A1 (en) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Phenyl substituted pyrazoles as modulators of roryt
WO2019244002A1 (en) * 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyridinyl pyrazoles as modulators of roryt
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
TW202146381A (en) * 2020-05-15 2021-12-16 大陸商上海輝启生物醫藥科技有限公司 Biaryl compound capable of serving as ror[gamma] regulator
WO2023146513A1 (en) * 2022-01-25 2023-08-03 Vivace Therapeutics, Inc. Compounds and methods of use thereof
CN116715613A (en) * 2023-05-09 2023-09-08 中山大学 ROR gamma covalent inhibition compound and preparation method and application thereof
WO2025141891A1 (en) * 2023-12-29 2025-07-03 キッセイ薬品工業株式会社 Biaryl compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012100734A1 (en) * 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) * 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012100734A1 (en) * 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) * 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2727191C2 (en) * 2015-06-05 2020-07-21 Лид Фарма Холдинг Б.В. ROR GAMMA (RORγ) MODULATORS
RU2727698C2 (en) * 2015-06-05 2020-07-23 Лид Фарма Холдинг Б.В. ROR GAMMA (RORγ) MODULATORS
US11299456B2 (en) * 2016-12-05 2022-04-12 Lead Pharma Holding B.V. ROR gamma (RORγ) modulators

Also Published As

Publication number Publication date
WO2013171729A2 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
WO2013171729A3 (en) Aryl and heteroaryl amide compounds as ror gamma t modulator
PH12016502045A1 (en) Aryl and heteroaryl ether compounds as ror gamma modulators
PH12016501105A1 (en) Bicyclic heteroaryl indole analogues useful as ror gamma modulators
MY198809A (en) Novel compounds as ror gamma modulators
WO2017087608A8 (en) Modulators of ror-gamma
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
MY174188A (en) Heterocyclyl compounds
HK1201819A1 (en) Novel compounds
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
MX383592B (en) Ror gamma (rory) modulators
PH12018501237A1 (en) Isoindole compounds
NZ702239A (en) Heteroaryl compounds and methods of use thereof
PH12018500411A1 (en) Novel carbocyclic compounds as ror gamma modulators
MX2015015741A (en) N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors.
EA201991373A1 (en) ROR GAMMA MODULATORS (RORγ)
WO2015031198A3 (en) Bendamustine pharmaceutical compositions
PH12016501215A1 (en) Azaindole derivative
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
TH157696A (en) Unclassified receptor modulators associated with gamma retinoids (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases.
HK1228393A1 (en) Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof
HK1244711A1 (en) Treatment of hmgb1-mediated inflammation
HK1233185A1 (en) Pharmaceutical compositions of therapeutically active compounds

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13767121

Country of ref document: EP

Kind code of ref document: A2